rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2014-10-4-402-405rpcardio-184Research ArticleASSOCIATED PROBLEMS OF CARDIOLOGYСМЕЖНЫЕ ПРОБЛЕМЫ КАРДИОЛОГИИRATIONAL PHARMACOTHERAPY BASED ON PHARMACOECONOMIC DATA AUDIT: PRINCIPLES AND APPLICATION IN BULGARIAРАЦИОНАЛЬНАЯ ФАРМАКОТЕРАПИЯ, ОСНОВАННАЯ НА РЕЗУЛЬТАТАХ ФАРМАКОЭКОНОМИЧЕСКОГО АУДИТА: ПРИНЦИПЫ И ПРИМЕНЕНИЕ В БОЛГАРИИВековТ. Й.VekovT.

д.м.н., профессор

Ул. Св. Климента Охридского 1, Плевен, 5800 Болгария

Sv. Kliment Ohridski str. 1, Pleven, 5800 Bulgaria

t.vekov.mu.pleven@abv.bgМедицинский университет ПлевенаБолгарияMedical University of PlevenBulgaria201423092015104402405Copyright © Vekov T., 20152015Веков Т.Й.Vekov T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/184

The theoretical foundations of the application of pharmacoeconomic evaluations of pharmacotherapies in order to improve their economic efficiency and support the process of taking decisions on their payment from public funds are examined. An algorithm is presented for the pharmacoeconomic audit, which is applicable for assessing the objectivity and reliability of the proposed pharmacoeconomic data from pharmaceutical manufacturers in the application process for inclusion in the positive list of medicines in Bulgaria and the reimbursement of economically rational pharmacotherapies from the public health fund.

Рассмотрены теоретические основы использования фармакоэкономического анализа для оценки альтернативных методов фармакотерапии с целью повышения экономической эффективности их использования и обеспечения возмещения их стоимости за счет государственных средств. Представлен алгоритм фармакоэкономического аудита, который применим для оценки достоверности фармакоэкономических данных, полученных от фармацевтических компаний при прохождении процедуры на включение в список разрешенных лекарств, затраты на которые возмещаются за счет госудственных средств.

факмакоэкономический аудитэкономически рациональные фармакотерапиивозмещение затратпозитивный список лекарственных средствpharmacoeconomic auditeconomically rational pharmacotherapiesreimbursementрositive list of medicinesReferencesLeopold C., Vagler S., Mantel-Teenwisse A. Differences in external price referencing in Europe – A descriptive overview. Health Policy 2012; 104(1): 50-60.Leopold C., Vagler S., Mantel-Teenwisse A. Differences in external price referencing in Europe – A descriptive overview. Health Policy 2012; 104(1): 50-60.Gandjour A. Reference Pricing and Price Negotiations for Innovative New Drugs, Viable Policies in the Long Term? Pharmaco Economics 2013; 31(1): 11-5.Gandjour A. Reference Pricing and Price Negotiations for Innovative New Drugs, Viable Policies in the Long Term? Pharmaco Economics 2013; 31(1): 11-5.Grieve R., Sadique M. Statistical methods for cost-effectiveness analyses that use observational data: A critical appraisal tool and review of current practice. Health Economics 2013; 22(4): 486-500.Grieve R., Sadique M. Statistical methods for cost-effectiveness analyses that use observational data: A critical appraisal tool and review of current practice. Health Economics 2013; 22(4): 486-500.Dakin H., Wordsworth S. Cost-minimisation analysis vs. cost-effectiveness analysis. Health Economics 2013; 22(1): 22-34.Dakin H., Wordsworth S. Cost-minimisation analysis vs. cost-effectiveness analysis. Health Economics 2013; 22(1): 22-34.Norman R., Hall J., Street D., Viney R. Efficiency and equity: A stated preference approach, Health Economics 2013; 22(5): 568-81.Norman R., Hall J., Street D., Viney R. Efficiency and equity: A stated preference approach, Health Economics 2013; 22(5): 568-81.Weinstein M. Economic assessments of medical practices and technologies. Medical Decision-Making 1981; 4: 309-30.Weinstein M. Economic assessments of medical practices and technologies. Medical Decision-Making 1981; 4: 309-30.Gold M., Siegel J., Russell L., Weinstein M. Cost-effectiveness in Health and Medicine. NY: Oxford University Press;1996.Gold M., Siegel J., Russell L., Weinstein M. Cost-effectiveness in Health and Medicine. NY: Oxford University Press;1996.Espin J., Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. European Commission, 2007. Available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/study_pricing_2007/andalusian_school_public_health_report_pricing_2007_en.pdf. Accessed by 20.06.2014.Espin J., Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. European Commission, 2007. Available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/study_pricing_2007/andalusian_school_public_health_report_pricing_2007_en.pdf. Accessed by 20.06.2014.Cabrales A., Jimenez-Martin S. The determinants of pricing in pharmaceuticals: Are US prices really so high? Health Economics 2013; 11: 1377-97.Cabrales A., Jimenez-Martin S. The determinants of pricing in pharmaceuticals: Are US prices really so high? Health Economics 2013; 11: 1377-97.Forster M., Pertile P. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective. Health Economics 2013; 12: 1507-14.Forster M., Pertile P. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective. Health Economics 2013; 12: 1507-14.Longworth L., Youn J., Bojke L. et al. When Does NICE Recommend the Use of Health Technologies Within a Program of Evidence Development? Pharmaco Economics 2013; 31(2): 137-50.Longworth L., Youn J., Bojke L. et al. When Does NICE Recommend the Use of Health Technologies Within a Program of Evidence Development? Pharmaco Economics 2013; 31(2): 137-50.Torrance G. Measurement of health state utilities for economic appraisal. J Health Economics 1986; 5:1-30.Torrance G. Measurement of health state utilities for economic appraisal. J Health Economics 1986; 5:1-30.

The authors declare that there are no conflicts of interest present.